Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disruption of temporo-parietal network in Alzheimer's disease and its association with memory impairment.

Alzheimer's research & therapy·2026
Same author

Symmetric Dimethylarginine for Risk Stratification of Cardioembolic Stroke.

Translational stroke research·2026
Same author

Diagnostic Images for Mild Cognitive Impairment Are Sensitive to Alzheimer's Disease Biomarkers and Reveal Abnormal Scene Processing.

Journal of cognitive neuroscience·2026
Same author

Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.

Nature communications·2026
Same author

The prevalence of insomnia disorder in inpatient psychiatric care.

European archives of psychiatry and clinical neuroscience·2026
Same author

Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

Nature genetics·2026

Related Experiment Video

Updated: Jul 12, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.

Hannelore Ehrenreich1, Benjamin Fischer, Christine Norra

  • 1Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Georg-August-University, Göttingen, Germany. ehrenreich@mpg.de

Brain : a Journal of Neurology
|August 31, 2007
PubMed
Summary

High-dose recombinant human erythropoietin (rhEPO) showed safety and potential efficacy in treating chronic progressive multiple sclerosis (MS). This neuroprotective approach improved motor and cognitive functions in MS patients, warranting further controlled trials.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jul 12, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Chronic progressive multiple sclerosis (MS) presents significant neurodegenerative challenges.
  • Current anti-inflammatory and immunosuppressive treatments for MS have limited success in halting neurodegeneration.
  • Recombinant human erythropoietin (rhEPO) exhibits promising neuroprotective effects in experimental models.

Purpose of the Study:

  • To evaluate the safety of long-term, high-dose intravenous rhEPO in patients with chronic progressive MS.
  • To gather preliminary evidence of rhEPO's efficacy on clinical outcomes in MS.
  • To assess rhEPO's impact on motor function and cognitive performance.

Main Methods:

  • An investigator-driven, exploratory open-label phase I/IIa study.
  • Eight chronic progressive MS patients received either high-dose (48,000 IU) or low-dose (8000 IU) rhEPO.
  • Two drug-naïve Parkinson's disease patients served as disease controls, receiving high-dose rhEPO.
  • Patients were monitored over 48 weeks, including treatment and post-treatment phases.

Main Results:

  • High-dose rhEPO treatment in MS patients led to clinical and electrophysiological improvements in motor function (reduced EDSS) and cognitive performance.
  • Observed benefits persisted for three to six months after rhEPO cessation.
  • Low-dose rhEPO and rhEPO in Parkinson's patients showed no significant improvements.
  • No adverse events or safety concerns were reported; blood-letting needs were minimal.

Conclusions:

  • High-dose rhEPO is safe and feasible for long-term administration in chronic progressive MS.
  • This study provides initial evidence for rhEPO's neuroprotective and potentially neuroregenerative effects in MS.
  • Controlled trials are necessary to confirm the efficacy of high-dose rhEPO in MS treatment.